文献速递心脑血管急症重症综合管理与镇静镇痛

N-甲基-D-天冬氨酸(NMDA)受体拮抗剂治疗创伤性脑损伤所致脑水肿的疗效:动物研究的系统评价与Meta分析

Efficacy of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Treating Traumatic Brain Injury-Induced Brain Edema: A Systematic Review and Meta-analysis of Animal Studies.
PubMed 文献 · Neurocrit Care · 2024-08-13
一句话结论动物研究Meta分析显示NMDA受体拮抗剂可显著减轻创伤性脑损伤后脑水肿(SMD -1.17)并改善神经行为评分,但异质性高(I2=72%)。

本系统评价遵循Cochrane手册指南并在PROSPERO注册(ID: CRD42023440934),纳入16项对照啮齿类动物研究,比较NMDA拮抗剂与安慰剂治疗创伤性脑损伤所致脑水肿。主要药物为艾芬地尔、MK-801、镁和HU-211,受试动物为Sprague-Dawley或Sabra大鼠。Meta分析显示NMDA拮抗剂显著减轻脑水肿(SMD -1.17,95%CI -1.59至-0.74,p<0.01),但异质性高(I2=72%);神经行为严重度量表也显著改善(均数差 -3.32,95%CI -4.36至-2.28,p<0.01)。伤后1小时内给药显示脑水肿减轻略有增强(SMD -1.23,95%CI -1.69至-0.77,p<0.01)。作者认为NMDA拮抗剂在创伤性脑损伤治疗中显示出有希望的疗效,但随机化、分配隐藏和盲法等关键偏倚常未报告。

要点

  • 动物研究Meta分析显示NMDA受体拮抗剂显著减轻创伤性脑损伤后脑水肿(SMD -1.17,95%CI -1.59至-0.74,p<0.01),异质性高(I2=72%)。
  • 神经行为严重度量表显著改善(均数差 -3.32,95%CI -4.36至-2.28,p<0.01)。
  • 伤后1小时内给药较基线显示脑水肿减轻略有增强(SMD -1.23,95%CI -1.69至-0.77,p<0.01)。
  • 主要药物为艾芬地尔、MK-801、镁和HU-211,受试动物为Sprague-Dawley或Sabra大鼠。
  • 随机化、分配隐藏和盲法等关键偏倚常未报告,基线可比性和选择性报告偏倚一般已处理。

适用人群与场景

  • 纳入对照啮齿类动物模型,比较NMDA拮抗剂与安慰剂治疗创伤性脑损伤所致脑水肿。
  • 受试动物为Sprague-Dawley或Sabra大鼠。

研究设计与关键结果

  • 系统评价遵循Cochrane手册指南,方案在PROSPERO注册(ID: CRD42023440934),纳入16项对照啮齿类动物研究。
  • 主要药物为艾芬地尔、MK-801、镁和HU-211,受试动物为Sprague-Dawley或Sabra大鼠。
  • NMDA拮抗剂治疗显著减轻脑水肿(SMD -1.17,95%CI -1.59至-0.74,p<0.01),异质性高(I2=72%)。
  • 神经行为严重度量表显著改善(均数差 -3.32,95%CI -4.36至-2.28,p<0.01)。
  • 伤后1小时内给药较基线显示脑水肿减轻略有增强(SMD -1.23,95%CI -1.69至-0.77,p<0.01)。
  • 研究符合动物福利和模型适当性标准;基线可比性和选择性报告偏倚一般已处理,但随机化、分配隐藏和盲法等关键偏倚常未报告。
  • 系统评价一致显示HU-211和NPS 150等化合物显著减轻脑水肿。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(动物研究)。
  • 使用CAMARADES清单和SYRCLE工具评估纳入研究的质量和偏倚。
  • 局限:异质性高(I2=72%);随机化、分配隐藏和盲法等关键偏倚常未报告。

对床旁实践的改变

  • 作者认为NMDA拮抗剂在创伤性脑损伤治疗中显示出有希望的疗效,系统评价一致显示HU-211和NPS 150等化合物显著减轻脑水肿。

指南或共识出处

  • Cochrane手册指南
  • PROSPERO注册(ID: CRD42023440934)
  • CAMARADES清单
  • SYRCLE工具

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Traumatic brain injury leads to glutamate release, which overstimulates N-methyl-D-aspartate (NMDA) receptors, leading to neurotoxicity and cytotoxic edema. NMDA receptor antagonists may offer neuroprotection by blocking this pathway. The objective of this systematic review is to assess the efficacy of NMDA receptor antagonists for traumatic brain injury-induced brain edema in rodent models. This systematic review followed Cochrane Handbook guidelines and registered its protocol in PROSPERO (ID: CRD42023440934). Here, we included controlled rodent animal models comparing NMDA antagonist use with a placebo treatment. Outcome measures included the reduction of cerebral edema, Neurobehavioral Severity Scale, and adverse effects. The search strategy used Medical Subject Headings terms related to traumatic brain injury and NMDA receptor antagonists. The Collaborative Approach to Meta Analysis and Review of Animal Experimental Studies (CAMARADES) checklist and Systematic Review Centre for Laboratory Animal Experimentation's (SYRCLE's) tools were used to measure the quality and bias of included studies. The synthesis of results was presented in a meta-analysis of standard mean difference. Sixteen studies were included, with the predominant drugs being ifenprodil, MK-801, magnesium, and HU-211. The subjects consisted of Sprague-Dawley or Sabra rats. The analysis showed a significant reduction in brain edema with NMDA antagonist treatment (Standardized mean difference [SMD] - 1.17, 95% confidence interval [CI] - 1.59 to - 0.74, p < 0.01), despite high heterogeneity (I2 = 72%). Neurobehavioral Severity Scale also significantly improved (mean difference - 3.32, 95% CI - 4.36 to - 2.28, p < 0.01) in animals receiving NMDA antagonists. Administration within 1 h after injury showed a modest enhancement in reducing brain edema compared with the baseline (SMD - 1.23, 95% CI - 1.69 to - 0.77, p < 0.01). Studies met standards for animal welfare and model appropriateness. Although baseline comparability and selective reporting bias were generally addressed, key biases such as randomization, allocation concealment, and blinding were often unreported. Overall, NMDA antagonists exhibit promising efficacy in the treatment of traumatic brain injury. Notably, our systematic review consistently demonstrated a significant reduction in brain edema with compounds including HU-211 and NPS 150.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Ribeiro FCP, de Oliveira NV, Coral GR, et al. Efficacy of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Treating Traumatic Brain Injury-Induced Brain Edema: A Systematic Review and Meta-analysis of Animal Studies. Neurocrit Care. 2024. PMID: 39138715. doi:10.1007/s12028-024-02079-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。